Last updated on November 2017

A randomized double blind placebo controlled dose ranging study to evaluate the efficacy and safety of IL-6Ra mAb in patients with Ankylosing Spondylitis


Brief description of study

A randomized double blind placebo controlled dose ranging study to evaluate the efficacy and safety of IL-6Ra mAb in patients with Ankylosing Spondylitis

Detailed Study Description

Do you have Ankylosing Spondylitis? You may qualify to participate in a clinical research study.

IL-6Ra mAb is a randomized placebo controlled trial of an injectable IL-6Rmab for patient with active sacroileitis from anklyosing spondylitis with active joint disease who are not responding to NSAIDs and are biologic agent naive. Prior DMARDs are allowed. There is 20 week treatment period.

Clinical Study Identifier: TX1261

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

The Center for Rheumatology and ...

The Center for Rheumatology and Bone Research
Wheaton, MD USA
  Connect »